Correction to: Prostate Cancer and Prostatic Diseases https://doi.org/10.1038/s41391-022-00533-6, published online 16 April 2022
In author contribution by MJ was given incorrectly as “Patient data and study materials, Manuscript editing and review”
but it should have been “Patient data and study materials, data analysis and interpretation, Manuscript editing and review.”
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Ohlmann, CH., Jäschke, M., Jaehnig, P. et al. Correction to: LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. Prostate Cancer Prostatic Dis 26, 812 (2023). https://doi.org/10.1038/s41391-023-00682-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-023-00682-2
